Aceon
(Perindopril)Phase 3Small molecule
Institut de Recherches Internationales ServierPerindopril is used to treat high blood pressure and to help the heart work more efficiently after a heart attack or in heart failure. It works by relaxing blood vessels to allow blood to flow more easily.[1] Aceon is currently being investigated across 3 indications[3], with its most advanced program in Phase 3.[1]
Aceon is one of 101 small molecule programs targeting Cardiovascular Disease. It is currently in Phase 3.
3
Indications
28
Total Trials
2
Active Trials
100
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
198 competitors in Heart Failure
#DrugCompanyPhaseTrials
1Aceon
Institut de Recherches Internationales ServierPhase 3
Brethine
SanofiPreclinical
Medrol
PfizerPreclinical
Activase
RochePreclinical
Zemplar
AbbViePreclinical
Savaysa
Daiichi SankyoPreclinical
Tamiflu
CConrado Roberto Hoffmann Filho
Preclinical
Oraverse
LLife Extension Foundation Inc.
Preclinical
GLP-1
RRigshospitalet, Denmark
Preclinical
Optimal Medical Therapy
HHelios Health Institute GmbH
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hypertension5 trials
Chronic Kidney Disease2 trials
Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease
Unknown status·—·Phase 4·NCT02299310·60 enrolled
Angiotensin Converting Enzyme2 trials
Blood Pressure2 trials
16 more indications
PTSD1 trial
DOXAZOSIN FOR PTSD
Completed·—·Phase 1·NCT02308202·30 enrolled
Marfan syndrome1 trial
Comparison of Medical Therapies in Marfan Syndrome.
Completed·—·Phase 4·NCT01295047·18 enrolled
Alcoholic Fatty Liver Disease1 trial
Essential Hypertension1 trial
Methamphetamine Dependence1 trial
An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence
Completed·—·Phase 1·NCT01062451·80 enrolled
Type 2 Diabetes1 trial
Fasting Conditions1 trial
Body Weight1 trial
Dilated Cardiomyopathy1 trial
PREclinical Mutation CARriers From Families With DIlated Cardiomyopathy and ACE Inhibitors
Terminated·IInstitut National de la Santé Et de la Recherche Médicale, France·Phase 3·NCT01583114·6 enrolled
Cerebral Small Vessel Disease1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Perindopril. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details